Fixed combination of repaglinide and metformin in the management of type 2 diabetes

Robert MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Treatment to target fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c are essential in the management of type 2 diabetes to reduce the risk of vascu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Robert Moses
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/be193c0f21574bcd8f8d324553d948c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:be193c0f21574bcd8f8d324553d948c1
record_format	dspace
spelling	oai:doaj.org-article:be193c0f21574bcd8f8d324553d948c12021-12-02T05:55:56ZFixed combination of repaglinide and metformin in the management of type 2 diabetes1178-7007https://doaj.org/article/be193c0f21574bcd8f8d324553d948c12009-06-01T00:00:00Zhttp://www.dovepress.com/fixed-combination-of-repaglinide-and-metformin-in-the-management-of-ty-a3289https://doaj.org/toc/1178-7007Robert MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Treatment to target fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c are essential in the management of type 2 diabetes to reduce the risk of vascular complications. Early combination therapy with oral agents is increasingly being seen as important to achieve this. Repaglinide, a rapid-acting insulin secretagogue, targets PPG, and metformin, an insulin sensitizer, targets FBG. Because of their complementary modes of action these therapies are frequently given as combination therapy in separate tablets. To overcome the issues with adherence to multiple tablets, repaglinide and metformin are now available in a fixed-dose combination (FDC). Repaglinide/metformin FDC is bioequivalent to each tablet given separately, suggesting that the efficacy and safety profile is similar. There is no effect of food on repaglinide when in the FDC. Repaglinide/metformin FDC is as effective in reducing HbA1c and FBG whether given twice or three times daily, with a similar safety profile. Repaglinide/metformin FDC twice daily is as effective in reducing HbA1c and FBG as rosiglitazone/metformin FDC with a similar safety profile, but unlike the rosiglitazone/metformin FDC, repaglinide/metformin FDC improves the lipid profile. Repaglinide/metformin FDC represents a new option in the pursuit of achieving glucose targets and reducing vascular risk in type 2 diabetes, with the advantage of improving adherence.Keywords: type 2 diabetes, metformin, repaglinide, fixed-dose combination Robert MosesDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2009, Iss default, Pp 101-109 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Robert Moses Fixed combination of repaglinide and metformin in the management of type 2 diabetes
description	Robert MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Treatment to target fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c are essential in the management of type 2 diabetes to reduce the risk of vascular complications. Early combination therapy with oral agents is increasingly being seen as important to achieve this. Repaglinide, a rapid-acting insulin secretagogue, targets PPG, and metformin, an insulin sensitizer, targets FBG. Because of their complementary modes of action these therapies are frequently given as combination therapy in separate tablets. To overcome the issues with adherence to multiple tablets, repaglinide and metformin are now available in a fixed-dose combination (FDC). Repaglinide/metformin FDC is bioequivalent to each tablet given separately, suggesting that the efficacy and safety profile is similar. There is no effect of food on repaglinide when in the FDC. Repaglinide/metformin FDC is as effective in reducing HbA1c and FBG whether given twice or three times daily, with a similar safety profile. Repaglinide/metformin FDC twice daily is as effective in reducing HbA1c and FBG as rosiglitazone/metformin FDC with a similar safety profile, but unlike the rosiglitazone/metformin FDC, repaglinide/metformin FDC improves the lipid profile. Repaglinide/metformin FDC represents a new option in the pursuit of achieving glucose targets and reducing vascular risk in type 2 diabetes, with the advantage of improving adherence.Keywords: type 2 diabetes, metformin, repaglinide, fixed-dose combination
format	article
author	Robert Moses
author_facet	Robert Moses
author_sort	Robert Moses
title	Fixed combination of repaglinide and metformin in the management of type 2 diabetes
title_short	Fixed combination of repaglinide and metformin in the management of type 2 diabetes
title_full	Fixed combination of repaglinide and metformin in the management of type 2 diabetes
title_fullStr	Fixed combination of repaglinide and metformin in the management of type 2 diabetes
title_full_unstemmed	Fixed combination of repaglinide and metformin in the management of type 2 diabetes
title_sort	fixed combination of repaglinide and metformin in the management of type 2 diabetes
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/be193c0f21574bcd8f8d324553d948c1
work_keys_str_mv	AT robertmoses fixedcombinationofrepaglinideandmetformininthemanagementoftype2diabetes
_version_	1718400134155337728

Fixed combination of repaglinide and metformin in the management of type 2 diabetes

Ejemplares similares